GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Accumulated other comprehensive income (loss)

Revelation Biosciences (FRA:56U0) Accumulated other comprehensive income (loss) : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Revelation Biosciences's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2024 was €0.00 Mil.

Revelation Biosciences Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Revelation Biosciences's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Accumulated other comprehensive income (loss) Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
- - - -

Revelation Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Revelation Biosciences Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Revelation Biosciences Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences (FRA:56U0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
FWBI NEXI ZVSA IPIX ENVB QLGN GRTX PSTV AXIM QRON OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
REVB:USA 56U1:Germany
Address
4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Website
https://www.revbiosciences.com
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines